Published Paper Details:

Original Research Article: STUDY OF EXPRESSION OF VARIOUS IMMUNOHISTOCHEMICAL MARKERS IN THE INVASIVE DUCTAL CARCINOMA OF BREAST (IDC). Authors: Dr. Jeel Sheth1, Dr. Rajvee Jadeja2 , Dr. Jasmin Jasani3, Dr. Yesha Chauhan4, Dr. Devansh Sheth5 1Resident, Department of Pathology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth. 2Resident, Department of Pathology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth. 3 Professor, Department of Pathology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth. 4 Resident, Department of Pathology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth.. 5 Third year MBBS student, B.J.Medical College, Gujarat University Ahmedabad ABSTRACT: INTRODUCTION: Breast cancer is the most frequent cancer in women worldwide, affecting one out of every eight women.(1) It accounts for 25% of all invasive cancers in females and 16% of all female malignancies. (2) The World Health Organization (WHO) reports that 685,000 women died from breast cancer in 2020, with an estimated 2.3 million women receiving a diagnosis worldwide. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life. (3) If detected at an early stage, breast cancer is curable. Prognostic factors are those that affect a patient's overall prognosis, such as the likelihood of recurrence following treatment. These variables aid in choosing the right patients for a certain treatment. (6) Tumor size, tumour grade, and axillary lymph node metastases are examples of conventional morphological prognostic variables. As a result of the fact that a considerable proportion of patients with early-stage breast cancer already have microscopic metastases when they are diagnosed, biological molecular prognostic markers are being given more weight.(7) The most relevant clinical biomarkers that are widely used in managing breast cancer cases according to stage are hormone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER-2).(7) Making management decisions and plans for breast cancer management requires an understanding of hormone receptors and HER-2 expressions. (8) In treatment of breast cancer, prognostic and predictive factors are used. Predictive factors assess the likelihood of benefit from a certain treatment. ER, PR, and HER2/neu are prognostic as well as predictive variables. (6) METHOD: This present study, entitled "IMMUNOHISTOCHEMICAL (IHC) EXPRESSION OF ESTROGEN RECEPTOR (ER), PROGESTERONE RECEPTOR (PR) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2/NEU) IN INVASIVE DUCTAL CARCINOMA OF BREAST: A CLINICOPATHOLOGICAL STUDY" is conducted in the Department of Pathology at Dhiraj hospital from 1st February 2023 to 31st August 2023. o The recorded data of IHC of patients who were diagnosed as invasive ductal carcinoma of breast that received in the department of pathology at Dhiraj hospital from 1st February 2023 to 31st August 2023. RESULT: The present study was undertaken to evaluate the various IHC markers expression in invasive ductal carcinoma of breast. Total of sixty cases who met the inclusion criteria were taken into the study. CONCLUSION: The present study reported maximum number of cases in the age group of 51-60 years. Majority of cases were in grade II followed by grade III and grade I. The highest proportion of positive ER (18.33%), and PR (16.67%) expressions were observed in the age group 51-60 years. The highest proportion of positive HER/2neu (10%) expression was observed in the age group 51-60 & 61-70 years.